|
1
|
Esteller M: Epigenetics in cancer. N Engl
J Med. 358:1148–1159. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rodríguez-Paredes M and Esteller M: Cancer
epigenetics reaches mainstream Oncology. Nat Med. 17:330–339. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yamamoto N, Nakayama T, Kajita M, Miyake
T, Iwamoto T, Kim SJ, Sakai A, Ishihara H, Tamaki Y and Noguchi S:
Detection of aberrant promoter methylation of GSTP1, RASSF1A, and
RARβ2 in serum DNA of patients with breast cancer by a newly
established one-step methylation-specific PCR assay. Breast Cancer
Res Treat. 132:165–173. 2012. View Article : Google Scholar
|
|
4
|
Fujita N, Nakayama T, Yamamoto N, Kim SJ,
Shimazu K, Shimomura A, Maruyama N, Morimoto K, Tamaki Y and
Noguchi S: Methylated DNA and total DNA in serum detected by
one-step methylation-specific PCR is predictive of poor prognosis
for breast cancer patients. Oncology. 83:273–282. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fujita N, Kagara N, Yamamoto N, Shimazu K,
Shimomura A, Shimoda M, Maruyama N, Naoi Y, Morimoto K, Oda N, et
al: Methylated DNA and high total DNA levels in the serum of
patients with breast cancer following neoadjuvant chemotherapy are
predictive of a poor prognosis. Oncol Lett. 8:397–403.
2014.PubMed/NCBI
|
|
6
|
Hoque MO, Feng Q, Toure P, Dem A,
Critchlow CW, Hawes SE, Wood T, Jeronimo C, Rosenbaum E, Stern J,
et al: Detection of aberrant methylation of four genes in plasma
DNA for the detection of breast cancer. J Clin Oncol. 24:4262–4269.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Avraham A, Uhlmann R, Shperber A, Birnbaum
M, Sandbank J, Sella A, Sukumar S and Evron E: Serum DNA
methylation for monitoring response to neoadjuvant chemotherapy in
breast cancer patients. Int J Cancer. 131:E1166–E1172. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sharma G, Mirza S, Parshad R, Gupta SD and
Ralhan R: DNA methylation of circulating DNA: A marker for
monitoring efficacy of neoadjuvant chemotherapy in breast cancer
patients. Tumour Biol. 33:1837–1843. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fackler MJ, Lopez Bujanda Z, Umbricht C,
Teo WW, Cho S, Zhang Z, Visvanathan K, Jeter S, Argani P, Wang C,
et al: Novel methylated biomarkers and a robust assay to detect
circulating tumor DNA in metastatic breast cancer. Cancer Res.
74:2160–2170. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Arai T, Miyoshi Y, Kim SJ, Taguchi T,
Tamaki Y and Noguchi S: Association of GSTP1 CpG islands
hypermethylation with poor prognosis in human breast cancers.
Breast Cancer Res Treat. 100:169–176. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Miyake T, Nakayama T, Naoi Y, Yamamoto N,
Otani Y, Kim SJ, Shimazu K, Shimomura A, Maruyama N, Tamaki Y, et
al: GSTP1 expression predicts poor pathological complete response
to neoadjuvant chemotherapy in ER-negative breast cancer. Cancer
Sci. 103:913–920. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mostowy S and Cossart P: Septins: The
fourth component of the cytoskeleton. Nat Rev Mol Cell Biol.
13:183–194. 2012.PubMed/NCBI
|
|
13
|
Robertson C, Church SW, Nagar HA, Price J,
Hall PA and Russell SE: Properties of SEPT9 isoforms and the
requirement for GTP binding. J Pathol. 203:519–527. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Peterson EA and Petty EM: Conquering the
complex world of human septins: Implications for health and
disease. Clin Genet. 77:511–524. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kalikin LM, Sims HL and Petty EM: Genomic
and expression analyses of alternatively spliced transcripts of the
MLL septin-like fusion gene (MSF) that map to a 17q25 region of
loss in breast and ovarian tumors. Genomics. 63:165–172. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Russell SE, McIlhatton MA, Burrows JF,
Donaghy PG, Chanduloy S, Petty EM, Kalikin LM, Church SW, McIlroy
S, Harkin DP, et al: Isolation and mapping of a human septin gene
to a region on chromosome 17q, commonly deleted in sporadic
epithelial ovarian tumors. Cancer Res. 60:4729–4734.
2000.PubMed/NCBI
|
|
17
|
Montagna C, Lyu MS, Hunter K, Lukes L,
Lowther W, Reppert T, Hissong B, Weaver Z and Ried T: The Septin 9
(MSF) gene is amplified and overexpressed in mouse mammary gland
adenocarcinomas and human breast cancer cell lines. Cancer Res.
63:2179–2187. 2003.PubMed/NCBI
|
|
18
|
Connolly D, Abdesselam I, Verdier-Pinard P
and Montagna C: Septin roles in tumorigenesis. Biol Chem.
392:725–738. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lofton-Day C, Model F, Devos T, Tetzner R,
Distler J, Schuster M, Song X, Lesche R, Liebenberg V, Ebert M, et
al: DNA methylation biomarkers for blood-based colorectal cancer
screening. Clin Chem. 54:414–423. 2008. View Article : Google Scholar
|
|
20
|
deVos T, Tetzner R, Model F, Weiss G,
Schuster M, Distler J, Steiger KV, Grützmann R, Pilarsky C,
Habermann JK, et al: Circulating methylated SEPT9 DNA in plasma is
a biomarker for colorectal cancer. Clin Chem. 55:1337–1346. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Warren JD, Xiong W, Bunker AM, Vaughn CP,
Furtado LV, Roberts WL, Fang JC, Samowitz WS and Heichman KA:
Septin 9 methylated DNA is a sensitive and specific blood test for
colorectal cancer. BMC Med. 9:1332011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Church TR, Wandell M, Lofton-Day C, Mongin
SJ, Burger M, Payne SR, Castaños-Vélez E, Blumenstein BA, Rösch T,
Osborn N, et al PRESEPT Clinical Study Steering Committee,
Investigators and Study Team: Prospective evaluation of methylated
SEPT9 in plasma for detection of asymptomatic colorectal cancer.
Gut. 63:317–325. 2014. View Article : Google Scholar :
|
|
23
|
Connolly D, Yang Z, Castaldi M, Simmons N,
Oktay MH, Coniglio S, Fazzari MJ, Verdier-Pinard P and Montagna C:
Septin 9 isoform expression, localization and epigenetic changes
during human and mouse breast cancer progression. Breast Cancer
Res. 13:R762011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Naoi Y, Kishi K, Tanei T, Tsunashima R,
Tominaga N, Baba Y, Kim SJ, Taguchi T, Tamaki Y and Noguchi S:
Development of 95-gene classifier as a powerful predictor of
recurrences in node-negative and ER-positive breast cancer
patients. Breast Cancer Res Treat. 128:633–641. 2011. View Article : Google Scholar
|
|
25
|
Parker JS, Mullins M, Cheang MC, Leung S,
Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, et al:
Supervised risk predictor of breast cancer based on intrinsic
subtypes. J Clin Oncol. 27:1160–1167. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mishima C, Kagara N, Tanei T, Naoi Y,
Shimoda M, Shimomura A, Shimazu K, Kim SJ and Noguchi S: Mutational
analysis of MED12 in fibroadenomas and phyllodes tumors of the
breast by means of targeted next-generation sequencing. Breast
Cancer Res Treat. 152:305–312. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pfütze K, Benner A, Hoffmeister M, Jansen
L, Yang R, Bläker H, Herpel E, Ulrich A, Ulrich CM, Chang-Claude J,
et al: Methylation status at HYAL2 predicts overall and
progression-free survival of colon cancer patients under 5-FU
chemotherapy. Genomics. 106:348–354. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lee ES, Issa JP, Roberts DB, Williams MD,
Weber RS, Kies MS and El-Naggar AK: Quantitative promoter
hypermethylation analysis of cancer-related genes in salivary gland
carcinomas: Comparison with methylation-specific PCR technique and
clinical significance. Clin Cancer Res. 14:2664–2672. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nygren AO, Ameziane N, Duarte HM,
Vijzelaar RN, Waisfisz Q, Hess CJ, Schouten JP and Errami A:
Methylation-specific mlPA (MS-MLPA): Simultaneous detection of CpG
methylation and copy number changes of up to 40 sequences. Nucleic
Acids Res. 33:e1282005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Toyota M, Kopecky KJ, Toyota MO, Jair KW,
Willman CL and Issa JP: Methylation profiling in acute myeloid
leukemia. Blood. 97:2823–2829. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Otani Y, Miyake T, Kagara N, Shimoda M,
Naoi Y, Maruyama N, Shimomura A, Shimazu K, Kim SJ and Noguchi S:
BRCA1 promoter methylation of normal breast epithelial cells as a
possible precursor for BRCA1-methylated breast cancer. Cancer Sci.
105:1369–1376. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tóth K, Galamb O, Spisák S, Wichmann B,
Sipos F, Valcz G, Leiszter K, Molnár B and Tulassay Z: The
influence of methylated septin 9 gene on RNA and protein level in
colorectal cancer. Pathol Oncol Res. 17:503–509. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Network CGA; Cancer Genome Atlas Network:
Comprehensive molecular portraits of human breast tumours. Nature.
490:61–70. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Amir S and Mabjeesh NJ: SEPT9_V1 protein
expression is associated with human cancer cell resistance to
microtubule-disrupting agents. Cancer Biol Ther. 6:1926–1931. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Froidevaux-Klipfel L, Poirier F, Boursier
C, Crépin R, Poüs C, Baudin B and Baillet A: Modulation of septin
and molecular motor recruitment in the microtubule environment of
the Taxol-resistant human breast cancer cell line MDA-MB-231.
Proteomics. 11:3877–3886. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chacko AD, McDade SS, Chanduloy S, Church
SW, Kennedy R, Price J, Hall PA and Russell SE: Expression of the
SEPT9_i4 isoform confers resistance to microtubule-interacting
drugs. Cell Oncol. 35:85–93. 2012. View Article : Google Scholar
|
|
37
|
Carey LA, Dees EC, Sawyer L, Gatti L,
Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ml and Perou
CM: The triple negative paradox: Primary tumor chemosensitivity of
breast cancer subtypes. Clin Cancer Res. 13:2329–2334. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Rouzier R, Perou CM, Symmans WF, Ibrahim
N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P,
et al: Breast cancer molecular subtypes respond differently to
preoperative chemotherapy. Clin Cancer Res. 11:5678–5685. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ignatiadis M and Sotiriou C: Luminal
breast cancer: from biology to treatment. Nat Rev Clin Oncol.
10:494–506. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Powrózek T, Krawczyk P, Kucharczyk T and
Milanowski J: Septin 9 promoter region methylation in free
circulating DNA-potential role in noninvasive diagnosis of lung
cancer: Preliminary report. Med Oncol. 31:9172014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ahmed D, Danielsen SA, Aagesen TH,
Bretthauer M, Thiis-Evensen E, Hoff G, Rognum TO, Nesbakken A,
Lothe RA and Lind GE: A tissue-based comparative effectiveness
analysis of biomarkers for early detection of colorectal tumors.
Clin Transl Gastroenterol. 3:e272012. View Article : Google Scholar
|
